<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924359/bin/CAM4-5-1022-g001.jpg"/> </div> <div class="text-side"> <h1>High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness.</h1> <p>Morphological characteristics of circulating tumor microemboli (CTMs) and iCTCs in metastatic malignant patients. (A–C). CTMs of different size composed of CNHC‐MF (A) or of CNHC‐MF and CNHC‐MF (B and C). (D). iCTCs corresponding to CNHC‐MF. (E). isolated circulating tumor cells (iCTCs) corresponding to CNHC‐UMF. (F). iCTCs corresponding to CNHC‐BF detected in a patient with benign nevi. (A–F). MGG, original magnification, ×1000.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26945789/" target="_blank">26945789</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>